May 24, 2021
April 21, 2021
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
March 17, 2021
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
February 25, 2021
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications
February 11, 2021
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts
November 5, 2020
Merck to Acquire VelosBio
October 16, 2020
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
September 16, 2020
selectION Secures $5M Promissory Note
July 20, 2020
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
July 8, 2020